Literature DB >> 28028062

Cardiovascular Effects of Performance-Enhancing Drugs.

André La Gerche1, Maria J Brosnan2.   

Abstract

Exercise and competitive sports should be associated with a wide range of health benefits with the potential to inspire a positive community health legacy. However, the reputation of sports is being threatened by an ever-expanding armamentarium of agents with real or perceived benefits in performance enhancement. In addition to the injustice of unfair advantage for dishonest athletes, significant potential health risks are associated with performance-enhancing drugs. Performance-enhancing drugs may have an effect on the cardiovascular system by means of directly altering the myocardium, vasculature, and metabolism. However, less frequently considered is the potential for indirect effects caused through enabling athletes to push beyond normal physiological limits with the potential consequence of exercise-induced arrhythmias. This review will summarize the known health effects of PEDs but will also focus on the potentially greater health threat posed by the covert search for performance-enhancing agents that have yet to be recognized by the World Anti-Doping Agency. History has taught us that athletes are subjected to unmonitored trials with experimental drugs that have little or no established efficacy or safety data. One approach to decrease drug abuse in sports would be to accept that there is a delay from when athletes start experimenting with novel agents to the time when authorities become aware of these drugs. This provides a window of opportunity for athletes to exploit with relative immunity. It could be argued that all off-label use of any agent should be deemed illegal.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  anabolic agents; arrhythmias, cardiac; erythropoietin; fibrosis; growth hormone; peptides; substance-related disorders

Mesh:

Substances:

Year:  2017        PMID: 28028062     DOI: 10.1161/CIRCULATIONAHA.116.022535

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Authors' Reply to Kindermann et al.'s Comment on: "Athlete's Heart: Diagnostic Challenges and Future Perspectives".

Authors:  Carlo De Innocentiis; Fabrizio Ricci; Mohammed Y Khanji; Nay Aung; Claudio Tana; Elvira Verrengia; Steffen E Petersen; Sabina Gallina
Journal:  Sports Med       Date:  2019-03       Impact factor: 11.136

Review 2.  Opinion paper: scientific, philosophical and legal consideration of doping in sports.

Authors:  Massimo Negro; Natale Marzullo; Francesca Caso; Luca Calanni; Giuseppe D'Antona
Journal:  Eur J Appl Physiol       Date:  2018-02-09       Impact factor: 3.078

3.  Sildenafil enhances central hemodynamic responses to exercise, but not V̇o2peak, in people with diabetes mellitus.

Authors:  Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche
Journal:  J Appl Physiol (1985)       Date:  2019-05-02

4.  Anabolic steroid misuse is an important reversible cause of cardiomyopathy: a case report.

Authors:  Stefan V Milevski; Matthew Sawyer; Andre La Gerche; Elizabeth Paratz
Journal:  Eur Heart J Case Rep       Date:  2022-07-02

Review 5.  Exercise and Coronary Atherosclerosis: Observations, Explanations, Relevance, and Clinical Management.

Authors:  Vincent L Aengevaeren; Arend Mosterd; Sanjay Sharma; Niek H J Prakken; Stefan Möhlenkamp; Paul D Thompson; Birgitta K Velthuis; Thijs M H Eijsvogels
Journal:  Circulation       Date:  2020-04-20       Impact factor: 29.690

Review 6.  Intense Endurance Exercise: A Potential Risk Factor in the Development of Heart Disease.

Authors:  Jocelynn Rajanayagam; Mohammed Alsabri
Journal:  Cureus       Date:  2021-01-10

7.  Doping Attitudes, Beliefs, and Practices among Young, Amateur Croatian Athletes.

Authors:  Ivan Miskulin; Danijela Stimac Grbic; Maja Miskulin
Journal:  Sports (Basel)       Date:  2021-02-09

8.  Associations between legal performance-enhancing substance use and future cardiovascular disease risk factors in young adults: A prospective cohort study.

Authors:  Jason M Nagata; Kyle T Ganson; Mitchell L Cunningham; Deborah Mitchison; Jason M Lavender; Aaron J Blashill; Holly C Gooding; Stuart B Murray
Journal:  PLoS One       Date:  2020-12-15       Impact factor: 3.240

Review 9.  Cardiac involvement in athletes infected by SARS COV-2 disease.

Authors:  J S Tasca; G Bianchi; A Girardello; A Lucchini; C Cappelli
Journal:  Sci Sports       Date:  2022-02-07       Impact factor: 0.987

Review 10.  American-Style Football and Cardiovascular Health.

Authors:  Jonathan H Kim; Ross Zafonte; Alvaro Pascuale-Leon; Lee M Nadler; Marc Weisskopf; Frank E Speizer; Herman A Taylor; Aaron L Baggish
Journal:  J Am Heart Assoc       Date:  2018-04-04       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.